A phase 2 clinical trial evaluating AP31969
Latest Information Update: 03 Oct 2023
At a glance
- Drugs AP-31969 (Primary)
- Indications Atrial fibrillation
- Focus Therapeutic Use
Most Recent Events
- 29 Sep 2023 According to an Acesion Pharma media release, the company closed an oversubscribed e45M Series B financing round the company is now well capitalized to progress AP31969 into a phase 1 and completion of a phase 2 trial.
- 28 Sep 2023 New trial record